

List of Figures

Figure No.	Description	Page No.
Figure 1.1	Chemical structure of Tetramethylpyrazine.	2
Figure 2.1	Pathophysiology of diabetes mellitus.	7
Figure 2.2	Pathophysiological progression of T2D.	12
Figure 2.3	The management paradigm for T2D: prevention of onset and proactive management of early-stage diabetes.	13
Figure 2.4	Different pathways and networks involved in the initiation and progression of DN. AGE, advanced glycation end product; CTGF, connective tissue growth factor; JAK/STAT, Janus kinase/signal transducer and activator of transcription; PKC, protein kinase C; RAAS, renin-angiotensin-aldosterone system; ROS, reactive oxygen species; SAA, serum amyloid A; VEGF-A, vascular endothelial growth factor A. *JAK/STAT signalling can be unchanged (\leftrightarrow) or upregulated (\uparrow) in early and later stages of diabetes, respectively.	19
Figure 2.5	Insulin signalling pathway. Insulin attaches to insulin receptors triggering its dimerisation and intracellular autophosphorylation of their tyrosine residues, which constitute an attachment for IRS proteins. These molecules also undergo phosphorylation and form a complex with PI3K utilising SH2 domains. PI3K phosphorylates PIP ₂ , which results in PIP ₃ formation and activation of PDK1/2. AKT gets phosphorylated and activated by PDK1/2, subsequently eliciting phosphorylation of AS160. The latter is responsible for GLUT-4 translocation to the cellular membrane and glucose inflow.	24
Figure 2.6	Role of Akt signalling pathway in the alleviation of renal apoptosis in DN.	26
Figure 5.1	Estimated insulin resistance (IR) and β -cell functioning (B%) from the HOMA model. All values are represented as mean \pm S.E.M. (n=6); Statistical significance was determined by one-way ANOVA followed by Tukey's multiple comparison post hoc test, and the significance was set at $P < 0.05$; where * represents significant difference compared to normal control, # represents significant difference compared to diabetic control; NC, normal control; DC, diabetic control; D,	53

diabetic; T-1, TMP (100mg/kg); T-2, TMP (150mg/kg); T-3, TMP (200mg/kg); TMP, tetramethylpyrazine; W, wortmannin (15 µg/kg).

- Figure 5.2 Effect of different doses of TMP on blood glucose level in OGTT. All values are represented as mean \pm S.E.M. (n=6); Statistical significance was determined by one-way ANOVA followed by Tukey's multiple comparison post hoc test, and the significance was set at $P < 0.05$; where * represents significant difference compared to normal control, # represents significant difference compared to diabetic control; NC, normal control; DC, diabetic control; D, diabetic; T-1, TMP (100mg/kg); T-2, TMP (150mg/kg); T-3, TMP (200mg/kg); TMP, tetramethylpyrazine; W, wortmannin (15 µg/kg). 54
- Figure 5.3 Effect of different doses of TMP on blood glucose level in ITT. All values are represented as mean \pm S.E.M. (n=6); Statistical significance was determined by one-way ANOVA followed by Tukey's multiple comparison post hoc test, and the significance was set at $P < 0.05$; where * represents significant difference compared to normal control, # represents significant difference compared to diabetic control; NC, normal control; DC, diabetic control; D, diabetic; T-1, TMP (100mg/kg); T-2, TMP (150mg/kg); T-3, TMP (200mg/kg); TMP, tetramethylpyrazine; W, wortmannin (15 µg/kg). 55
- Figure 5.4 Effect of TMP treatment on HbA1c (%) in HFD-STZ-induced diabetic rats. All values are represented as mean \pm S.E.M. (n=6); Statistical significance was determined by one-way ANOVA followed by Tukey's multiple comparison post hoc test, and the significance was set at $P < 0.05$; where * represents significant difference compared to normal control, # represents significant difference compared to diabetic control; NC, normal control; DC, diabetic control; D, diabetic; T-1, TMP (100mg/kg); T-2, TMP (150mg/kg); T-3, TMP (200mg/kg); TMP, tetramethylpyrazine; W, wortmannin (15 µg/kg). 56
- Figure 5.5 Effect of TMP treatment on lipid profile levels in the serum of HFD-STZ-induced diabetic rats. All values are represented as mean \pm S.E.M. (n=6); Statistical significance was determined by one-way ANOVA followed by Tukey's multiple comparison post hoc test, and the significance was 58

set at $P < 0.05$; where * represents significant difference compared to normal control, # represents significant difference compared to diabetic control; NC, normal control; DC, diabetic control; D, diabetic; T-1, TMP (100mg/kg); T-2, TMP (150mg/kg); T-3, TMP (200mg/kg); TMP, tetramethylpyrazine; W, wortmannin (15 $\mu\text{g}/\text{kg}$).

Figure 5.6 Effect of TMP treatment on IL-6 and CRP levels in the serum of HFD–STZ-induced diabetic rats. All values are represented as mean \pm S.E.M. (n=6); Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparison post hoc test, and the significance was set at $P < 0.05$; where * represents significant difference compared to normal control, # represents significant difference compared to diabetic control; NC, normal control; DC, diabetic control; D, diabetic; T-1, TMP (100mg/kg); T-2, TMP (150mg/kg); T-3, TMP (200mg/kg); TMP, tetramethylpyrazine; W, wortmannin (15 $\mu\text{g}/\text{kg}$). 59

Figure 5.7 Analysis of the effect of TMP administration on the expression of the insulin signalling pathway proteins PI3K, Akt and GLUT4 in the skeletal muscle, heart and adipose tissue of HFD–STZ-induced diabetic rats through western blotting; a relative expression of p-PI3K-p85, b Relative expression of p-Akt, c relative expression of GLUT-4. Experiments were 3 times repeated independently. The shown blots were the outcome of one of the experiments. Intensities of band in each blot were determined after normalisation by the corresponding total protein, and the values are represented as mean \pm S.E.M., n = 3 independent experiments. Differences were estimated by one-way ANOVA followed by Tukey’s multiple comparison post hoc tests and the significance was set at $P < 0.05$; where * represents significant difference compared to normal control, # represents significant difference compared to diabetic control; NC, normal control; DC, diabetic control; D, diabetic; T-1, TMP (100mg/kg); T-2, TMP (150mg/kg); T-3, TMP (200mg/kg); TMP, tetramethylpyrazine; W, wortmannin (15 $\mu\text{g}/\text{kg}$). 63

Figure 5.8 Confirmation of the effect of TMP administration on the expression of genes corresponding to the proteins of insulin signalling pathway PI3K, Akt and GLUT4 in the skeletal muscle, heart and adipose tissue of HFD–STZ-induced 65

diabetic rats through qRT-PCR. The relative level of expression for the indicated genes compared to normal control was determined by the $2^{-\Delta\Delta C_t}$ method using β -actin gene as a normaliser. The average relative expression determined in three independent experiments ($n = 3$) is plotted on the histogram with error bars representing the S.E.M. Differences were estimated by one-way ANOVA followed by Tukey's multiple comparison post hoc tests and the significance was set at $P < 0.05$; where * represents significant difference compared to normal control, # represents significant difference compared to diabetic control; NC, normal control; DC, diabetic control; D, diabetic; T-1, TMP (100mg/kg); T-2, TMP (150mg/kg); T-3, TMP (200mg/kg); TMP, tetramethylpyrazine; W, wortmannin (15 μ g/kg).

- Figure 5.9 Effect of TMP administration on (A) body weight, (B) FBG level and (C) FSI level of experimental rats. All values are expressed as mean \pm S.E.M., $n=6$; Statistical differences were evaluated by one-way ANOVA followed by Tukey's multiple comparison post hoc test, and the significance level was set at $P < 0.05$; where * denotes statistical significance compared to NC, and # denotes statistical significance compared to DC; NC, normal control; DC, diabetic control; D, diabetic; T-1, TMP (100mg/kg); T-2, TMP (150mg/kg); T-3, TMP (200mg/kg); TMP, tetramethylpyrazine. 68
- Figure 5.10 Effect of TMP administration on blood glucose level in OGTT of experimental rats. All values are expressed as mean \pm S.E.M., $n=6$; Statistical differences were evaluated by one-way ANOVA followed by Tukey's multiple comparison post hoc test, and the significance level was set at $P < 0.05$; where * denotes statistical significance compared to NC, and # denotes statistical significance compared to DC; NC, normal control; DC, diabetic control; D, diabetic; T-1, TMP (100mg/kg); T-2, TMP (150mg/kg); T-3, TMP (200mg/kg); TMP, tetramethylpyrazine. 69
- Figure 5.11 Effect of TMP administration on glycosylated haemoglobin (HbA1c-%) level of experimental rats. All values are expressed as mean \pm S.E.M., $n=6$; Statistical differences were evaluated by one-way ANOVA followed by Tukey's multiple comparison post hoc test, and the significance level was set at $P < 0.05$; where * denotes statistical significance 69

compared to NC, and # denotes statistical significance compared to DC; NC, normal control; DC, diabetic control; D, diabetic; T-1, TMP (100mg/kg); T-2, TMP (150mg/kg); T-3, TMP (200mg/kg); TMP, tetramethylpyrazine.

- Figure 5.12 Effect of TMP administration on serum lipid profile levels of experimental rats. All values are expressed as mean \pm S.E.M., n=6; Statistical differences were evaluated by one-way ANOVA followed by Tukey's multiple comparison post hoc test, and the significance level was set at $P < 0.05$; where * denotes statistical significance compared to NC, and # denotes statistical significance compared to DC; NC, normal control; DC, diabetic control; D, diabetic; T-1, TMP (100mg/kg); T-2, TMP (150mg/kg); T-3, TMP (200mg/kg); TMP, tetramethylpyrazine. 71
- Figure 5.13 Effect of TMP on kidney and serum oxidative stress parameters of experimental rats. A, SOD activity in kidney and serum; B, MDA activity in kidney and serum; C, GSH-Px activity in kidney and serum. All values are expressed as mean \pm S.E.M., n=6; Statistical differences were evaluated by one-way ANOVA followed by Tukey's multiple comparison post hoc test, and the significance level was set at $P < 0.05$; where * denotes statistical significance compared to NC, and # denotes statistical significance compared to DC; NC, normal control; DC, diabetic control; D, diabetic; T-1, TMP (100mg/kg); T-2, TMP (150mg/kg); T-3, TMP (200mg/kg); TMP, tetramethylpyrazine. 74
- Figure 5.14 Effect of TMP treatment on kidney function parameters of diabetic rats. BUN level (A), SCR level (B) and 24-hour urinary protein content (C) were measured. All values are expressed as mean \pm S.E.M., n=6; Statistical differences were evaluated by one-way ANOVA followed by Tukey's multiple comparison post hoc test, and the significance level was set at $P < 0.05$; where * denotes statistical significance compared to NC, and # denotes statistical significance compared to DC; NC, normal control; DC, diabetic control; D, diabetic; T-1, TMP (100mg/kg); T-2, TMP (150mg/kg); T-3, TMP (200mg/kg); TMP, tetramethylpyrazine. 76
- Figure 5.15 Histopathological analysis of TMP treatment effect on renal morphology of diabetic rats. (A) Typical HE staining photomicrograph indicating effect of TMP treatment on glomerular mesangial matrix expansion, scale bar: 50 μ m, 80

magnification: X40; (B) Values of GMEI; (C) HE staining photomicrograph showing TMP treatment effect on the tubulointerstitial injury, scale bar: 50 μ m, magnification: X40; (D) Values of TDI. All values are expressed as mean \pm S.E.M., n=6; Statistical differences were evaluated by one-way ANOVA followed by Tukey's multiple comparison post hoc test, and the significance level was set at $P < 0.05$; where * denotes statistical significance compared to NC, and # denotes statistical significance compared to DC; NC, normal control; DC, diabetic control; D, diabetic; T-1, TMP (100mg/kg); T-2, TMP (150mg/kg); T-3, TMP (200mg/kg); TMP, tetramethylpyrazine; HE, hematoxylin and eosin.

- Figure 5.16 Analysis of the TMP treatment effect on the expression of the Akt signalling pathway proteins in the kidney tissue of STZ-NCT-induced diabetic rats through western blotting (A); (B) relative expression of p-Akt, (C) relative expression of p-GSK-3 β , (D) relative expression of Bcl-2, (E) relative expression of Bax, (F) relative expression of cleaved caspase-3. Experiments were independently repeated 3 times. The shown blots were the result of one of the investigation. Intensities of the band in each blot were evaluated after normalisation by the corresponding total protein, and the values are presented as mean \pm S.E.M., where n = 3 independent experiments. Differences were evaluated by one-way ANOVA followed by Tukey's multiple comparison post hoc tests, and the significance level was set at $P < 0.05$; where * denotes statistical significance compared to NC, and # denotes statistical significance compared to DC. NC, normal control; DC, diabetic control; D, diabetic; T-1, TMP (100mg/kg); T-2, TMP (150mg/kg); T-3, TMP (200mg/kg); TMP, tetramethylpyrazine. 83
- Figure 6.1 Illustration of the mechanism of action of TMP in amelioration of HFD-STZ-induced T2D in rats. Abbreviations: TMP, tetramethylpyrazine; PI3K, phosphatidylinositol-3-kinase; Akt, protein kinase B; GLUT-4, glucose transporter-4; HFD, high-fat diet; STZ, streptozotocin; T2D, type-2 diabetes; SM, skeletal muscle; H, heart; AT, adipose tissue; \uparrow , increase; \downarrow , decrease; +, activation; -, inhibition. 89
- Figure 6.2 Elucidation of the mechanism of action of TMP in the amelioration of diabetic nephropathy in STZ-NCT-induced T2D rats. 93